Arvinas

ARVN

Market cap $699M

– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany.

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease –

NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform presentation, featuring clinical data for ARV-102, an investigational oral PROTAC (PROteolysis TArgeting Chimera) degrader of leucine-rich repeat kinase 2 (LRRK2), will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders® (MDS 2025) being held October 5–9, 2025, in Honolulu.

Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.

Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with Pfizer Inc. (NYSE: PFE) for the co-development of vepdegestrant, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader, and announced additional corporate actions to support shareholder value creation.

Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the afternoon session.

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor conferences:

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –

Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.